Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.54 |
| ▸ | MTOR | P42345 | 12/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.49 |
| ▸ | ATR | Q13535 | 3/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011124 | 0.93 | ATR (0.52) | PIK3CAMTORPIK3CGATRPIK3CD | |
| SCHEMBL4009774 | 0.89 | PIK3CA (0.51) | PIK3CAMTORPIK3CGATRPIK3CD | |
| SCHEMBL4004756 | 0.88 | ATR (0.60) | PIK3CAMTORATRPIK3CD | |
| SCHEMBL27793996 | 0.86 | PIK3CA (0.49) | PIK3CAMTORPIK3CGATRPIK3CD | |
| SCHEMBL3932094 | 0.86 | MTOR (0.60) | PIK3CAMTORPIK3CGATRPIK3CD | |
| SCHEMBL4196219 | 0.84 | PIK3CA (0.55) | PIK3CAMTORPIK3CGATRPIK3CD | |
| SCHEMBL3936091 | 0.84 | PIK3CA (0.62) | PIK3CAMTORPIK3CGATRPIK3CD | |
| SCHEMBL4007338 | 0.84 | MTOR (0.57) | PIK3CAMTORPIK3CGATRPIK3CD | |
| SCHEMBL8091768 | 0.82 | PIK3CA (0.46) | PIK3CAMTORPIK3CGATRPIK3CD | |
| SCHEMBL4003358 | 0.82 | PIK3CA (0.52) | PIK3CAMTORPIK3CGATRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | PIK3CA 2/4885MTOR 1/4885PIK3CG 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.